Monday, June 18, 2018 -- (Reuters) - Valeant Pharmaceuticals International Inc's plaque psoriasis treatment did not get approval from U.S. health regulators, a setback for the company which had high hopes for the lotion.
Monday, June 18, 2018 -- Patients with psoriasis who were treated with adalimumab had a reduction in key markers of inflammation such as glycoprotein acetylation compared with those treated with phototherapy, according to a study published in Circulation: Cardiovascular Imaging.“[Tumor necrosis factor, interleukin-6, C-reactive protein and glycoprotein acetylation] are known to predict future cardiovascular events, and thus reducing these markers of inflammation suggests a cardioprotective effect,” Joel M. Gelfand, MD, MSCE, professor of dermatology and epidemiology, vice chair of clinical research,
Tuesday, June 19, 2018 -- The US FDA has rejected Valeant Pharmaceutical Internationalâs investigational topical treatment for plaque psoriasis, Duobrii.
Wednesday, June 20, 2018 -- A new study by iData Research estimates that there are nearly 150,000 new cases of psoriasis every year in the United States, affecting 2.2% of the population.
Wednesday, June 20, 2018 -- NewsThe FDA has issued a Complete Response Letter to Valeant for its Duobrii lotion. The agency did not specify any deficiencies related to the clinical efficacy or safety, but noted questions regarding pharmacokinetic data.Contributed Author: Valeant Pharmaceuticals International, Inc.Topics: Regulatory